Panacea Biotec

Panacea Biotec surges 4% on reports of launching dengue vaccine in two yrs

Shares of Panacea Biotec surged up to 4.48 per cent at Rs 319.40 on the BSE in Friday's intraday trade

Panacea Biotec gets $20 mn loan from US DFC for capex; stock rises 5%

The shares of Panacea Biotec rose after the company announced that it has secured $20 million in loan from US International Development Finance Corp (DFC).

DFC commits long-term loan of $20 mn to Panacea Biotec to expand operations

US International Development Finance Corporation (DFC) has committed a long-term loan of up to USD 20 million to Panacea Biotec, the company said on Thursday. Panacea is expanding the manufacturing capacity for drug substance antigens used in its hexavalent vaccine EasySix to meet future demand from UN agencies and public health organisations. DFC has agreed to provide a long-term loan of up to USD 20 million to the company to help finance this project, the biotechnology firm said in a regulatory filing. DFC's financing will enable Panacea Biotec to expedite the completion of the ongoing expansion and supply the hexavalent vaccine to UN agencies for childhood immunisation globally, it added. "Our hexavalent vaccine EasySix, which meets the highest standards of safety and efficacy, will have a meaningful impact on the lives of millions of newborns in the developing world," Panacea Biotec Chairman and MD Rajesh Jain said. DFC Deputy CEO Nisha Biswal said the organisation's partnersh

Panacea Biotec freezes in 10% upper circuit; stock zooms 101% in 1 month

A combined 2.1 million equity shares of the company had changed hands till 02:50 PM, and there are pending buy orders for nearly 100,000 shares on the NSE and BSE.

Apotex seeks $118 million from Panacea for collaboration pact breach

Canada-based Apotex Inc has sought USD 118.14 million from Panacea Biotec over breach of a collaboration agreement inked in 2014, the capital-based drug firm said on Thursday. The company has received a notification dated October 4 from the International Court of Arbitration, Paris, intimating that an arbitration proceeding has been initiated as per a request by Apotex Inc, Panacea Biotec said in a regulatory filing. Apotex has alleged that the company has breached its obligations under the collaboration agreement for research, development, licence, supply and sale of products inked on May 9, 2014, it added. Apotex has alleged that there has been a purported delay in seeking approval from US Food and Drug Administration for the product mentioned in the said agreement, Panacea Biotec said. "Apotex has claimed USD 118.14 million towards outsized alleged losses plus interest thereon to the extent permissible under the applicable law," it added. The company believes it is not in breac

Expensive deal valuations to hit Torrent Pharma's near-term earnings

Sales trajectory in domestic formulations and resolution of regulatory issues are other triggers

USFDA asks Panacea Biotec to take corrective measures at Himachal unit

Panacea Biotec Ltd on Thursday said the US health regulator has asked for further corrective actions at the manufacturing unit of its wholly-owned arm at Baddi in Himachal Pradesh otherwise approval of any pending product applications from the facility may be withheld. The US Food and Drug Administration (USFDA) had inspected the Baddi unit of its subsidiary, Panacea Biotec Pharma Ltd (PBPL) from May 30 to June 8, 2022. Subsequently, the USFDA issued Form 483 with eight observations which are related to improvements in existing procedures and are addressable, Panacea Biotec said in a regulatory filing. According to the US Food and Drug Administration (USFDA), Form 483 is issued to a firm's management at the conclusion of an inspection when the investigator has observed any conditions that may constitute violations of the Food Drug and Cosmetic (FD&C) Act and related Acts. The company said it has "now received a communication from the USFDA indicating the inspection classification .

Stocks to Watch: Airtel, Indiabulls Housing, Panacea Biotec, Tata Power

Panacea Biotec may see some action on plans to launch a comprehensive coronavirus vaccine in association with THSTI.

Panacea Biotec, THSTI tie up to make broad Covid vax, trials in 15-18 mths

If things go according to plan this India-made vaccine could hit the market within the next two to three years

Mankind Pharma signs agreement to buy Panacea Biotec Pharma's domestic biz

Panacea Biotec Pharma is a subsidiary of vaccine maker Panacea Biotec; its domestic biz had a turnover of Rs 219 cr in FY21; Adar Poonawalla holds 8.6% stake in the firm

DRL steps up Sputnik V supplies with second dose from Panacea Biotec

Hospital industry sources claim they want assurance on shelf life of imported vaccines

Panacea Biotec supplies second component of Sputnik V vaccine in India

Panacea Biotec has supplied the first shipment of the second component of the Russian Sputnik V vaccine manufactured by it for sale in India.

Panacea Biotec surges 9% on DCGI's nod to produce Sputnik V vaccine

Sputnik V was registered in India under the emergency use authorization procedure on April 12, 2021 and vaccination against Covid-19 with the Russian vaccine started on May 14, 2021

Top headlines: Grasim Q4 net rises 13%; BSE sees a new milestone

Business Standard brings you the top news of the evening

Panacea Biotec to make 100 mn doses of Sputnik V for global markets

More players like Serum Institute expected to join the fray to make Sputnik V

Shot of Hope: Equal access a hurdle after race to coronavirus vaccine

The second of a two-part series examines challenges linked to IPR and monopoly once Covid-19 vaccine is created

Panacea Biotec surges 20% on pact with US firm Refana for Covid-19 vaccine

The stock is trading close to its 52-week high level of Rs 210.60, touched on April 28, 2020

Panacea Biotec hits 52-week high; stock rallies 64% in 4 days

The stock has more-than-doubled in the past one month from the level of Rs 101, as compared to 6.6 per cent gain in Sensex in the same period

Panacea Biotec surges 10% on collaboration with Serum Institute of India

The stock surges 10% to Rs 284 after the company signed two long term agreements with Serum Institute of India and its wholly owned subsidiary, Bilthovan Biologicals BV

USFDA accepts Panacea Biotec's ANDA for generic cancer drug

This product is a generic version of Abraxane, which is used for treatment of breast cancer, non-small lung cancer and adenocarcinoma of pancreas, it said.